UBS Group’s Kiora Pharmaceuticals KPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.51K | Buy |
1,301
+389
| +43% | +$821 | ﹤0.01% | 9261 |
|
|
2025
Q4 | $1.8K | Sell |
912
-452
| -33% | -$1.03K | ﹤0.01% | 9468 |
|
|
2025
Q3 | $3.79K | Sell |
1,364
-16,280
| -92% | -$44.7K | ﹤0.01% | 9012 |
|
|
2025
Q2 | $50.8K | Buy |
17,644
+17,642
| +882,100% | +$53.8K | ﹤0.01% | 7756 |
|
|
2025
Q1 | $6 | Hold |
2
| – | – | ﹤0.01% | 10135 |
|
|
2024
Q4 | $7 | Sell |
2
-352
| -99% | -$1.22K | ﹤0.01% | 9821 |
|
|
2024
Q3 | $1.29K | Sell |
354
-7,966
| -96% | -$31.1K | ﹤0.01% | 8668 |
|
|
2024
Q2 | $34.9K | Buy |
+8,320
| New | +$38.8K | ﹤0.01% | 6963 |
|
|
2024
Q1 | – | Sell |
-246
| Closed | -$1.15K | – | 9705 |
|
|
2023
Q4 | $1.15K | Buy |
246
+83
| +51% | +$431 | ﹤0.01% | 8391 |
|
|
2023
Q3 | $834 | Buy |
163
+162
| +16,200% | +$829 | ﹤0.01% | 8251 |
|
|
2023
Q2 | $5 | Sell |
1
-17
| -94% | -$356 | ﹤0.01% | 8766 |
|
|
2023
Q1 | $555 | Sell |
18
-455
| -96% | -$17K | ﹤0.01% | 8977 |
|
|
2022
Q4 | $14.6K | Buy |
473
+235
| +99% | +$10.8K | ﹤0.01% | 8061 |
|
|
2022
Q3 | $13K | Buy |
238
+158
| +198% | +$12.3K | ﹤0.01% | 8043 |
|
|
2022
Q2 | $13K | Buy |
80
+79
| +7,900% | +$13.2K | ﹤0.01% | 7515 |
|
|
2022
Q1 | $0 | Sell |
1
-56
| -98% | -$14.6K | ﹤0.01% | 10594 |
|
|
2021
Q4 | $31K | Buy |
57
+56
| +5,600% | +$31.6K | ﹤0.01% | 7362 |
|
|
2021
Q3 | $1K | Hold |
1
| – | – | ﹤0.01% | 9201 |
|
|
2021
Q2 | $1K | Sell |
1
-11
| -92% | -$17.1K | ﹤0.01% | 9158 |
|
|
2021
Q1 | $21K | Buy |
12
+1
| +9% | +$2.18K | ﹤0.01% | 7334 |
|
|
2020
Q4 | $20K | Buy |
11
+10
| +1,000% | +$13.8K | ﹤0.01% | 6943 |
|
|
2020
Q3 | $2K | Sell |
1
-6
| -86% | -$9.44K | ﹤0.01% | 7666 |
|
|
2020
Q2 | $12K | Buy |
7
+3
| +75% | +$5.63K | ﹤0.01% | 6890 |
|
|
2020
Q1 | $7K | Buy |
4
+2
| +100% | +$4.3K | ﹤0.01% | 7144 |
|
|
2019
Q4 | $6K | Buy |
2
+1
| +100% | +$1.94K | ﹤0.01% | 7515 |
|
|
2019
Q3 | $2K | Sell |
1
-10
| -91% | -$11.5K | ﹤0.01% | 7734 |
|
|
2019
Q2 | $14K | Buy |
11
+10
| +1,000% | +$14.8K | ﹤0.01% | 6843 |
|
|
2019
Q1 | $2K | Sell |
1
-4
| -80% | -$9.72K | ﹤0.01% | 7448 |
|
|
2018
Q4 | $13K | Buy |
5
+4
| +400% | +$9.23K | ﹤0.01% | 7094 |
|
|
2018
Q3 | $1K | Sell |
1
-2
| -67% | -$5.37K | ﹤0.01% | 7835 |
|
|
2018
Q2 | $8K | Buy |
+3
| New | +$8.46K | ﹤0.01% | 7259 |
|
|
2018
Q1 | – | Sell |
-1
| Closed | -$4.32K | – | 7643 |
|
|
2017
Q4 | $5K | Buy |
+1
| New | +$6.18K | ﹤0.01% | 7379 |
|
|
2017
Q1 | – | Hold |
0
| – | -$4K | – | 7806 |
|
|
2016
Q4 | – | Hold |
0
| – | – | – | 7323 |
|
|
2016
Q3 | – | Sell |
-1
| Closed | -$8K | – | 7814 |
|
|
2016
Q2 | $8K | Buy |
+1
| New | +$17.4K | ﹤0.01% | 6899 |
|
|
2016
Q1 | – | Hold |
0
| – | – | – | 7312 |
|
|
2015
Q4 | – | Sell |
-1
| Closed | -$16.1K | – | 7778 |
|
|
2015
Q3 | $11K | Buy |
+1
| New | +$22.9K | ﹤0.01% | 7204 |
|
Other funds holding KPRX
ACM
VCM
XT
VFT
TSS
RC
TRCT
UBS Group's KPRX Position: Q1 2026 in Review
UBS Group increased its Kiora Pharmaceuticals (KPRX) stake by 43% in Q1 2026, buying an estimated $821 and bringing the position to 1,301 shares worth $2.51K. The position accounts for ﹤0.01% of the portfolio, ranked #9261.
UBS Group first reported a position in KPRX in Q3 2015 and has held it in 34 quarters since. The position peaked at $50.8K in Q2 2025. 18 funds tracked by Wall St. Rank hold KPRX as of Q1 2026.
- UBS Group held 1,301 shares of Kiora Pharmaceuticals worth $2.51K as of Q1 2026.
- UBS Group bought 389 Kiora Pharmaceuticals shares in Q1 2026, an estimated $821.
- Kiora Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #9261 holding.
- UBS Group first reported a position in Kiora Pharmaceuticals in Q3 2015 and has held it in 34 quarters since.
- UBS Group's Kiora Pharmaceuticals position peaked at $50.8K in Q2 2025.
- 18 funds tracked by Wall St. Rank held Kiora Pharmaceuticals as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.